Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians-Reference-Cited by-同舟云学术

Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians

Published:2021-12-02 Issue:1 Volume:23 Page:61-67
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Muzumdar Sonal,Skudalski Lauren,Sharp Kelley,Waldman Reid A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-021-00646-z.pdf

Reference39 articles.

1. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update (review). Experimental and Therapeutic Medicine [Internet]. Spandidos Publications; 2019 [cited 2021 Apr 17];17:1061–7. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/30679974/.

2. Gooderham MJ, Hong HC ho, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2018 [cited 2021 Apr 17];78:S28–36. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/29471919/.

3. Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 Submissions to the US FDA’s Office of Clinical Pharmacology. Journal of Clinical Pharmacology [Internet]. Blackwell Publishing Inc.; 2020 [cited 2021 Apr 17];60:S160–78. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/33205429/.

4. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];82:377–88. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31374300/.

5. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatology [Internet]. American Medical Association; 2020 [cited 2021 Apr 17];156:131–43. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31876900/.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open‐label case series study;Journal of the European Academy of Dermatology and Venereology;2024-08-06

2. Tonic type 2 immunity is a critical tissue checkpoint controlling autoimmunity in the skin;Cell Reports;2024-07

3. Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice;Journal of Clinical Medicine;2024-06-28

4. Nicotiana benthamiana-derived dupilumab-scFv reaches deep into the cultured human nasal epithelial cells and inhibits CCL26 expression;Scientific Reports;2024-06-24

5. Tralokinumab‐related facial redness: a therapeutic challenge;International Journal of Dermatology;2024-06-06